By Andreas Persidis, CEO Biovista Inc. Are you by any chance, like me, beginning to get the feeling that when you are searching online, your digital profile may be getting in the way? That too much of this “personalized” cerebral pampering, too much of this “right information, to the right person at the right time” … Read More
Why Systematic Drug Repurposing (SDR) is here to stay. The article gives 5 reasons why SDR will continue to be used as a tool for developing new therapies that are more affordable and make better use of our existing knowledge of disease pathology, drug performance and other date from the real world evidence surrounding treatments.
Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey A new paper co-authored by Biovista and the Solve ME/CFS Initiative has just been published. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, poorly understood disorder that causes only a small number of the approximately 2.5 million Americans to receive proper diagnosis. … Read More
CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ — Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. “We look forward to working with the Drug Repurposing … Read More
CHARLOTTESVILLE, Virginia, September 2, 2015 /PRNewswire/ — Biovista Inc. is glad to announce the sponsoring of the winners of the 2015 BeHEARD science challenge, a global competition hosted by the Rare Genomics Institute that offers rare disease researchers, access to the latest life science innovations and technologies.